October 22, 2014 / 1:28 PM / 3 years ago

BUZZ-U.S. Stocks on the Move-Ebola-related stocks, Cree, Biogen, Broadcom

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)

U.S. stock index futures pointed to a very slightly higher open on Wednesday, with buyers largely taking a pause following the biggest four-day rally for the S&P 500 since January 2013. Dow Jones industrial average futures were up 0.10 percent at 16,564, S&P 500 futures were unchanged at 1,938 and Nasdaq 100 futures were down 0.03 percent at 3,970.5.

** DOW CHEMICAL CO, Tuesday close $48.21, +3.30 pct premarket

The No. 1 U.S. chemical maker by sales, reported a better-than-expected quarterly profit for the fourth time in a row, helped by higher sales in its plastics and performance materials business units.

** BOEING, Tuesday close $127.12, +0.69 pct premarket

The aircraft maker reported an 18 percent increase in quarterly profit and raised its full-year core earnings forecast for the third time, reflecting booming commercial aircraft demand.

** 3D SYSTEMS CORP, Tuesday close $43.38, -16.07 pct premarket

The three-dimensional printer maker estimated quarterly revenue well below the average analyst estimate, citing manufacturing constraints for its direct metal printers.

** JOHNSON & JOHNSON, Tuesday close $100.36, +0.76 pct premarket

** GLAXOSMITHKLINE PLC, Tuesday close $43.63, +2.06 pct premarket

** NEWLINK GENETICS, Tuesday close $34.5, +1.59 pct premarket

** TEKMIRA PHARMACEUTICALS CORP, Tuesday close $17.98, +11.62 pct premarket

Shares of companies developing Ebola vaccines rose before the bell. Leading drugmakers plan to work together to accelerate development of an Ebola vaccine and produce millions of doses of the most effective experimental product for use next year.

J&J said it was accelerating work on its experimental Ebola vaccine and aims to produce 1 million doses next year, 250,000 of which are expected to be available by May.

J&J has already discussed collaboration with GSK, which is working on a rival vaccine.

Separately, Tekmira said it started limited manufacturing of its therapeutic targeting Ebola. The company said its RNAi therapeutic, which works by preventing virus from replicating, is part of its TKM-Ebola program and would be available by early December.

** ORAMED PHARMACEUTICALS INC, Tuesday close $7.95, +6.92 pct premarket

Oramed said its oral insulin capsule appeared to be safe and was well-tolerated by diabetics in a mid-stage trial.

** BIOGEN IDEC, Tuesday close $326.77, -6.67 pct premarket

The biotechnology company’s third quarter sales of its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time.

“Generally a solid quarter, though a slight Tecfidera miss and lack of revenue guidance raise might disappoint some,” Wells Fargo analyst Brian Abrahams wrote in a note.

** CREE INC, Tuesday close $33.15, -10.41 pct premarket

At least seven brokerages cut their price targets on the light-emitting diode maker’s stock by as much as $14 to as low as $28. The stock has a median price target of $33.50.

The company on Tuesday reported lower-than-expected quarterly profit and revenue and forecast current-quarter adjusted profit and revenue below the average analyst estimate due to weak demand for LEDs.

** BROADCOM CORP, Tuesday close $37.33, +7.21 pct premarket

Four brokerages raised their price targets on the chipmaker’s stock after third-quarter results of the company, whose wifi connectivity chips are used in Apple’s iPhones, exceeded Wall Street’s estimates on Tuesday.

“We like Broadcom stock, which we think should continue to rerate higher from its current low valuation as the focus shifts towards the company’s strengths in networking, infrastructure, and broadband,” Morgan Stanley said in a note to clients.

Morgan Stanley raised its price target on the stock to $47 from $44, above the median price target of $45.

** UNISYS CORP, Tuesday close $19.38, +18.94 pct premarket

The IT company posted on Tuesday a third-quarter profit compared with a year-earlier loss. Revenue rose 11 percent, driven by growth in its technology and services businesses.

** YAHOO INC, Tuesday close $40.18, +5.70 pct premarket

Yahoo’s CEO is trying to steer investor focus away from the tech company’s stagnant revenue and toward achievements and growth prospects that have been flying below the radar.

Chief Executive Marissa Mayer spent much of Tuesday’s earnings call highlighting improvements in Yahoo’s mobile business, the benefits from acquisitions and billions of dollars in buybacks.

** ABBOTT LABORATORIES, Tuesday close $42.39, +2.03 pct premarket

** MYLAN INC, Tuesday close $52.045

Abbott said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan.

** SIX FLAGS ENTERTAINMENT CORP, Tuesday close $34.5, +12.64 pct premarket

The theme park operator reported on Tuesday better-than-expected third-quarter revenue, helped by an 8 percent rise in admissions revenue per capita.

** VMWARE INC, Tuesday close $88.19, -8.15 pct premarket

The software maker forecast current-quarter revenue largely below Wall Street’s estimates due to a delay in the closing of a large U.S. government deal and lower bookings in Germany, Russia and Japan in the third quarter.

** COCA-COLA CO, Tuesday close $40.68, -1.18 pct premarket

The world’s largest beverage maker announced new cost-cutting measures on Tuesday and a timeline for selling its bottling operations after its quarterly profit slumped 14 percent as it the struggled to find growth amid a soft market for soda.

The company said it would hand back, or refranchise, about two-thirds of its North American bottling territories by the end of 2017.

** APPLE INC, Tuesday close $102.47, +0.22 pct premarket

The iPhone maker and GT Advanced Technologies Inc struck an agreement on Tuesday that will let GT begin the shutdown of key Arizona operations, and shed some more light on why the former stock market darling abruptly filed for bankruptcy this month.

** TESLA MOTORS INC, Tuesday close $235.34, -1.20 pct premarket

Michigan Governor Rick Snyder signed a bill on Tuesday that will keep the electric carmaker from selling its cars directly to consumers in the state, home to the biggest U.S. automakers.

** SUSSER PETROLEUM PARTNERS LP, Tuesday close $46.43, -2.41 pct premarket

The motor fuel distributor said on Tuesday that it started an offering of 8 million units, representing about 36 percent of its total outstanding units. Susser intends to use the proceeds to repay debt under its revolving credit facility.

The company also said it expects third-quarter results to be hurt by non-cash charges of $2 million-$2.5 million related to Susser Holdings Corp’s acquisition by Energy Transfer Partners LP.

** IROBOT CORP, Tuesday close $31.61, +10.63 pct premarket

The robot maker’s third-quarter profit nearly doubled and revenue and profit both beat analysts’ average estimates. The company also raised its full-year profit forecast on Tuesday.

IRobot said orders in both its home as well as defense and security businesses that were originally expected in the fourth quarter were received and delivered in the third quarter.

** OCWEN FINANCIAL CORP, Tuesday close $21.48, -7.77 pct premarket

Two brokerages cut their ratings on the mortgage servicing company’s stock after New York state’s financial regulator said on Tuesday that Ocwen may have harmed borrowers by sending them backdated letters about loan modifications and foreclosures.

Evercore downgraded the stock to “hold” from “buy,” and BofA Merrill Lynch to “neutral” from “buy”. Citigroup cut its target price on the stock to $23 from $32. The stock has a median target price of $29.

** INTUITIVE SURGICAL INC, Tuesday close $495.77, +1.16 pct premarket

Intuitive showed signs on Tuesday of bouncing back from a difficult first half of the year as sales of its da Vinci robotic surgical systems increased in the third quarter, as did procedures using the company’s high-priced machines.

** VERTEX PHARMACEUTICALS INC, Tuesday close $108.16

A U.S. Food and Drug Administration advisory panel voted 13-2 on Tuesday to recommend expanding approval of Vertex’s cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.

** GFI GROUP, Tuesday close $5.13, +2.14 pct premarket

** BGC PARTNERS INC, Tuesday close $7.49, -100.00 pct premarket

Rival BGC launched a hostile $675 million bid for the interdealer broker after talks between two companies reached a deadlock.

BGC said it commenced an all-cash tender offer of $5.25 per share for the 86.5 percent of GFI it does not already own.

** SONIC CORP, Tuesday close $23.57, +1.32 pct premarket

The drive-in restaurant chain operator’s fourth-quarter sales beat the average analyst estimate helped by a 4.6 percent rise in same-store sales growth.

The company said it expects fiscal 2015 same-store sales to grow in “low single digit” percentage range, and drive-in margins to improve 50-100 basis points.

** ALLERGAN INC, Tuesday close $10.56

** VALEANT PHARMACEUTICALS, Tuesday close $130.38

Allergan said on Tuesday it saw no evidence to support claims by hostile suitors Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management that its chief executive had spearheaded a campaign to spread misinformation. (Compiled by Shailaja Sharma in Bangalore; Editing by Simon Jennings)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below